TY - JOUR
T1 - Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure
AU - Barutaut, Manon
AU - Fournier, Pauline
AU - Peacock, William F.
AU - Evaristi, Maria Francesca
AU - Caubere, Celine
AU - Turkieh, Annie
AU - Desmoulin, Franck
AU - Eurlings, Luc W. M.
AU - van Wijk, Sandra
AU - Brunner-La Rocca, Hans-Peter
AU - Butler, Javed
AU - Koukoui, Francois
AU - Dambrin, Camille
AU - Mazeres, Serge
AU - Le Page, Servane
AU - Delmas, Clement
AU - Galinier, Michel
AU - Jung, Christian
AU - Smih, Fatima
AU - Rouet, Philippe
N1 - Funding Information:
This work was funded by Fondation Coeur et Recherche (FCR). FCR had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript. We thank Sandrine Masson for samples and clinical data collection.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Background: Insulin-like Growth Factor Binding Protein 2 (IGFBP2) showed greater heart failure (HF) diagnostic accuracy than the "grey zone" B-type natriuretic peptides, and may have prognostic utility as well.Objectives: To determine if IGFBP2 provides independent information on cardiovascular mortality in HF.Methods: A retrospective study of 870 HF patients from 3 independent international cohorts. Presentation IGFBP2 plasma levels were measured by EUSA, and patients were followed from 1 year (Maastricht. Netherlands) to 6 years (Atlanta, GA, USA and Toulouse, France). Multivariate analysis, Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI) were performed in the 3 cohorts. The primary outcome was cardiovascular mortality.Results: In multivariate Cox proportional hazards analysis, the highest quartile of IGFBP2 was associated with mortality in the Maastricht cohort (adjusted hazard ratio 1.69 (95% CI 1.18-2.41), p = 0.004) and in the combined Atlanta and Toulouse cohorts (adjusted hazard ratio 2.04 (95%CI, 13-3.3), p = 0.003). Adding IGFBP2 to a clinical model allowed a reclassification of adverse outcome risk in the Maastricht cohort (NRI - 18.7% p = 0.03; IDI - 3.9% p = 0.02) and with the Atlanta/Toulouse patients (NRI of 40.4% p = 0.01, 31,2% p = 0.04, 315% p = 0,02 and IDI of 2,9% p = 0,0005, 3.1% p = 0,0005 and 4,2%, p = 0.0005, fora follow-up of 1, 2 and 3 years, respectively).Conclusion: In 3 international cohorts, IGFBP2 level is a strong prognostic factor for cardiovascular mortality in HF, adding information to natriuretic monitoring and usual clinical markers, that should be further prospectively evaluated for patients optimized care. (C) 2019 Elsevier B.V. All rights reserved.
AB - Background: Insulin-like Growth Factor Binding Protein 2 (IGFBP2) showed greater heart failure (HF) diagnostic accuracy than the "grey zone" B-type natriuretic peptides, and may have prognostic utility as well.Objectives: To determine if IGFBP2 provides independent information on cardiovascular mortality in HF.Methods: A retrospective study of 870 HF patients from 3 independent international cohorts. Presentation IGFBP2 plasma levels were measured by EUSA, and patients were followed from 1 year (Maastricht. Netherlands) to 6 years (Atlanta, GA, USA and Toulouse, France). Multivariate analysis, Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI) were performed in the 3 cohorts. The primary outcome was cardiovascular mortality.Results: In multivariate Cox proportional hazards analysis, the highest quartile of IGFBP2 was associated with mortality in the Maastricht cohort (adjusted hazard ratio 1.69 (95% CI 1.18-2.41), p = 0.004) and in the combined Atlanta and Toulouse cohorts (adjusted hazard ratio 2.04 (95%CI, 13-3.3), p = 0.003). Adding IGFBP2 to a clinical model allowed a reclassification of adverse outcome risk in the Maastricht cohort (NRI - 18.7% p = 0.03; IDI - 3.9% p = 0.02) and with the Atlanta/Toulouse patients (NRI of 40.4% p = 0.01, 31,2% p = 0.04, 315% p = 0,02 and IDI of 2,9% p = 0,0005, 3.1% p = 0,0005 and 4,2%, p = 0.0005, fora follow-up of 1, 2 and 3 years, respectively).Conclusion: In 3 international cohorts, IGFBP2 level is a strong prognostic factor for cardiovascular mortality in HF, adding information to natriuretic monitoring and usual clinical markers, that should be further prospectively evaluated for patients optimized care. (C) 2019 Elsevier B.V. All rights reserved.
KW - IGFBP2
KW - Biomarker
KW - Heart failure
KW - Prognosis
KW - Nathuretic peptides
KW - Cardiovascular mortality
KW - FACTOR-I
KW - NATRIURETIC PEPTIDE
KW - HORMONE THERAPY
KW - BIOMARKER
KW - CARDIOMYOPATHY
KW - PHOSPHATASE
KW - EXPRESSION
KW - SYSTEM
U2 - 10.1016/j.ijcard.2019.09.032
DO - 10.1016/j.ijcard.2019.09.032
M3 - Article
C2 - 31806281
SN - 0167-5273
VL - 300
SP - 245
EP - 251
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -